Colorectal cancer is becoming a growing crisis, especially among younger adults. It is now a leading cause of cancer death in people under 50, with cases rising about 3% each year in those aged 20 to 49, even as rates fall in older adults. Many younger patients are diagnosed late, with nearly 75% already at advanced or metastatic stages. This often happens because early warning signs, such as rectal bleeding, are mistaken for minor problems like hemorrhoids. In addition, early-onset disease tends to be more aggressive and often affects the lower part of the colon and rectum.
Experts believe this trend is driven by a mix of lifestyle and environmental factors. Diets high in processed foods and sugary drinks, along with obesity and alcohol use, may increase risk. Changes in gut bacteria, including the presence of Fusobacterium nucleatum, are also being studied, along with the possible impact of antibiotics and environmental exposures such as microplastics.
In response, screening guidelines now recommend starting at age 45 instead of 50. There is also growing use of noninvasive tests like Cologuard Plus, which offers high sensitivity and greater convenience. Treatment is also evolving, with doctors using molecular profiling to guide therapy. New drugs are targeting specific mutations such as KRAS, and emerging treatments like Amivantamab and Telisotuzumab adzuxecan aim to overcome resistance. However, finding effective treatments remains a challenge for many patients, particularly those with mismatch repair–proficient disease.